Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

301.64 -6.36 (-2.06%)
Streaming Delayed Price Updated: 3:09 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all... 
Via Benzinga
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Five Best And Worst Performing Healthcare Stocks In December 2022
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
3 Growth Stocks That Could Rocket Higher in 2023
Upcoming binary events could push these stocks to new all-time highs. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
Alnylam Announces Updates to its Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
From Alnylam Pharmaceuticals
Via Business Wire
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
Via Benzinga
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter. 
Via Benzinga
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program
Via Benzinga
Alnylam Pharmaceuticals: Q3 Earnings Insights
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.